drugset / Trial / NCT00102817

Somatropin (Norditropin) in Insulin-like Growth Factor (IGF) Deficient Children

NCT00102817

Phase 3 Completed 149 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in the United States of America (USA). This is a 12 month study to determine if Norditropin is safe and effective in children with IGF deficiency.

Timeline

Start
2003-05
Primary completion
2006-12
Completion
2006-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Somatropin Protein / enzyme biologic 40 ug/kg